| A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy S Pei, IT Shelton, AE Gillen, BM Stevens, M Gasparetto, Y Wang, L Liu, ... Cancer discovery 13 (9), 2032-2049, 2023 | 45 | 2023 |
| Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal L Weinkle, CH Domen, I Shelton, S Sillau, K Nair, E Alvarez Multiple sclerosis and related disorders 27, 383-390, 2019 | 31 | 2019 |
| Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium AI Sheth, MJ Althoff, H Tolison, K Engel, ML Amaya, AE Krug, TN Young, ... Cancer Discovery, 2024 | 8 | 2024 |
| Tolerability and safety of switching from rituximab to ocrelizumab: evaluating factors associated with infusion related reactions E Alvarez, KV Nair, S Sillau, I Shelton, R Seale, S Selva, J Corboy, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 8 (1 …, 2022 | 7 | 2022 |
| Evaluating the tolerability and safety of switching from rituximab to ocrelizumab: infusion related reactions in relapsing forms of multiple sclerosis (P4. 2-015) E Alvarez, K Nair, I Shelton, S Selva, N Voge, N Zanganeh, S Sillau, ... Neurology 92 (15_supplement), P4. 2-015, 2019 | 4 | 2019 |
| Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia M Minhajuddin, A Winters, H Ye, S Pei, B Stevens, A Gillen, K Engel, ... Haematologica 110 (1), 103, 2024 | 2 | 2024 |
| Cost and Return on Investment of a Team-Based Palliative Care Program for Parkinson Disease RB McQueen, M Gritz, D Kern, JL Bemski, I Shelton, M Meyer, BM Kluger Neurology: Clinical Practice 12 (6), 429-437, 2022 | 2 | 2022 |
| Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells AI Sheth, K Engel, H Tolison, MJ Althoff, A Krug, ML Amaya, S Pei, ... Blood 142, 588, 2023 | 1 | 2023 |
| Serum neurofilament levels in long term rituximab treated multiple sclerosis patients: are we over or under treating? E Alvarez, K Nair, A Ritchie, I Shelton, S Gendelman, S Sillau, G Owens, ... MULTIPLE SCLEROSIS JOURNAL 25, 923-924, 2019 | 1 | 2019 |
| Evaluating the tolerability and safety profile of switching from rituximab to ocrelizumab: infusion related reactions in relapsing forms of multiple sclerosis E Alvarez, K Nair, I Shelton, N Zanganeh, S Sillau, J Corboy, T Vollmer MULTIPLE SCLEROSIS JOURNAL 24, 710-710, 2018 | 1 | 2018 |
| No Effect Of Body Mass Index On Serum Neurofilament Light In Long Term Rituximab Treated Multiple Sclerosis Patients: The Need To Correct For Age, Blood Volume, And Disability E Alvarez, SZ Gendelman, KV Nair, A Ritchie, IT Shelton, SH Sillau, ... MULTIPLE SCLEROSIS JOURNAL 26 (1_ SUPPL), 23-23, 2020 | | 2020 |
| Risk Factors in Early Multiple Sclerosis (RISEMS) I Shelton, J Corboy, E Alvarez, C Musser MULTIPLE SCLEROSIS JOURNAL 25, 281-282, 2019 | | 2019 |
| Characterizing cytokine changes before and after ocrelizumab infusions and their contribution to infusion related reactions E Alvarez, K Nair, I Shelton, S Sillau, S Selva, T Vollmer MULTIPLE SCLEROSIS JOURNAL 25, 505-506, 2019 | | 2019 |
| Cannabis use by Patients with Multiple Sclerosis in Colorado (P3. 2-092) C Domen, L Weinkle, I Shelton, S Sillau, K Nair, E Alvarez Neurology 92 (15_supplement), P3. 2-092, 2019 | | 2019 |
| Characterizing cytokine changes before and after ocrelizumab infusions and their contribution to infusion related reactions I Shelton, N Zanganeh, S Selva, S Sillau, K Nair, T Vollmer, E Alvarez MULTIPLE SCLEROSIS JOURNAL 24, 884-885, 2018 | | 2018 |
| Exploring Cannabis use by Patients with Multiple Sclerosis in a state where Cannabis is legal (P2. 419) LJ Weinkle, I Shelton, SH Sillau, C Domen, KV Nair, E Alvarez Neurology 90 (15_supplement), P2. 419, 2018 | | 2018 |
